Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

CMS selects next batch of 15 high-cost medicines for third negotiation cycle

The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.

Latest news

UK and certain European countries lose WHO’s measles-free status

WHO has called for urgent political and financial commitment from countries to eliminate the disease.

Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies

Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.

FDA accepts Otsuka’s centanafadine application for ADHD treatment

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

UK biotechs suffered restricted financing in 2025

Despite a lacklustre year for UK biotech funding, M&A pickup and trade deals could drive growth rebound.

FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

High-dose biologic delivery to become industry standard

As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will play a growing role for drugmakers.